| Drugs by Condition |  |
Respiratory Distress Syndrome
Definition: A condition of the newborn marked by dyspnea with cyanosis, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.
Drugs associated with Respiratory Distress Syndrome
The following drugs and medications are in some way related to, or used in the treatment of Respiratory Distress Syndrome.
This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Drug Name  ( View by: Brand | Generic )
|
Reviews | Ratings |
|---|---|---|
Survanta Intratracheal (More...) generic name: beractant class: lung surfactants | 0 Review(s) | Not rated - Be the first |
Respiratory Distress Syndrome Related Drugs in the Pipeline
Surfaxin (lucinactant)
- May 5, 2008
Discovery Labs Provides Guidance On FDA Approvable Letter for Surfaxin for RDS - May 2, 2008
Discovery Labs Receives An Approvable Letter From FDA for Surfaxin for RDS - November 16, 2007
Discovery Labs' Response to Surfaxin Approvable Letter Deemed Complete by FDA - November 1, 2007
Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin for RDS in Premature Infants - October 1, 2007
Surfaxin Process Validation Batches Achieve Stability Milestone to Enable Filing of Response to FDA Approvable Letter - August 2, 2007
Discovery Labs Provides Update On Progress for Surfaxin for RDS - January 22, 2007
Discovery Labs and FDA Reach Clarity On Path Towards Surfaxin RDS Approval - September 28, 2006
Discovery Labs Updates Progress On Manufacturing Remediation and Surfaxin FDA Regulatory Matters - April 5, 2006
Discovery Labs Receives Second Approvable Letter From FDA for Surfaxin for RDS - October 21, 2005
FDA Accepts Discovery Labs' Complete Response to Approvable Letter for Surfaxin - August 19, 2005
Discovery Labs Provides Update on Status of Response to FDA Approvable Letter for Surfaxin - August 15, 2005
Discovery Labs Provides Status of Previously Submitted Response to FDA Approvable Letter for Surfaxin - July 29, 2005
Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin for RDS in Premature Infants - February 14, 2005
Discovery Labs Receives Approvable Letter from FDA for Surfaxin for Respiratory Distress Syndrome in Premature Infants - June 15, 2004
Discovery Laboratories Announces FDA Acceptance of Surfaxin New Drug Application - April 14, 2004
Discovery Laboratories Files New Drug Application with the FDA to Market Surfaxin for the Prevention of Respiratory Distress Syndrome in Premature Infants
